Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „tezacaftor“
Suchtreffer
Begriffe & Kennungen
Kalydeco · 4.8 · 16 Ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor
Eintrag öffnenKalydeco · 4.8 · During the 24-week, placebo-controlled, phase 3 study of ivacaftor/tezacaftor/elexacaftor, these figures were
Eintrag öffnenKalydeco · 4.8 · During the 24-week, placebo-controlled, phase 3 study of ivacaftor/tezacaftor/elexacaftor, these figures were
Eintrag öffnenKalydeco · 4.8 · During the placebo-controlled phase 3 studies (up to 24 weeks) of tezacaftor/ivacaftor, the incidence of maxim
Eintrag öffnenKalydeco · 4.8 · During the placebo-controlled phase 3 studies (up to 24 weeks) of tezacaftor/ivacaftor, the incidence of maxim
Eintrag öffnenKalydeco · 4.8 · In study 445-102, the incidence of rash events (e.g., rash, rash pruritic) was 10.9% in ivacaftor/tezacaftor/e
Eintrag öffnenKalydeco · 4.8 · In study 445-102, the incidence of rash events (e.g., rash, rash pruritic) was 10.9% in ivacaftor/tezacaftor/e
Eintrag öffnenKalydeco · 4.8 · Ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor
Eintrag öffnenKalydeco · 4.8 · Ivacaftor in a combination regimen with tezacaftor/ivacaftor
Eintrag öffnenKalydeco · 4.8 · Ivacaftor in a combination regimen with tezacaftor/ivacaftor
Eintrag öffnenKalydeco · 4.8 · The safety data of ivacaftor/tezacaftor/elexacaftor in combination with ivacaftor in studies 445-102, 445-103,
Eintrag öffnenKalydeco · 4.8 · The safety data of ivacaftor/tezacaftor/elexacaftor in combination with ivacaftor in studies 445-102, 445-103,
Eintrag öffnenKalydeco · 4.8 · The safety of tezacaftor/ivacaftor in combination with ivacaftor was evaluated in 124 patients between 6 to le
Eintrag öffnenKalydeco · 4.8 · The safety of tezacaftor/ivacaftor in combination with ivacaftor was evaluated in 124 patients between 6 to le
Eintrag öffnenSymkevi · 4.5 · Co-administration of ciprofloxacin did not affect the exposure of ivacaftor or tezacaftor. No dose adjustment
Eintrag öffnenSymkevi · 4.5 · Co-administration with itraconazole, a strong CYP3A inhibitor, increased tezacaftor exposure (measured as AUC)
Eintrag öffnenSymkevi · 4.5 · In vitro studies showed that tezacaftor is a substrate for the uptake transporter OATP1B1, and efflux transpor
Eintrag öffnenSymkevi · 4.5 · Medicinal products affected by tezacaftor and ivacaftor
Eintrag öffnenSymkevi · 4.5 · Medicinal products affecting the pharmacokinetics of tezacaftor and ivacaftor
Eintrag öffnenSymkevi · 4.5 · Potential for tezacaftor/ivacaftor to interact with transporters
Eintrag öffnen